Ipsen giv­en an ad­comm date for palo­varotene; Am­brx Bio­phar­ma looks to se­cure $75M in lat­est se­cu­ri­ties of­fer­ing

Ipsen has been giv­en an ad­vi­so­ry com­mit­tee date of June 28 for its re­sub­mit­ted NDA for palo­varotene as a po­ten­tial treat­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.